SCHEMBL2907387

SCHEMBL2907387

CN1CCN(Cc2cn(-c3ccccc3)nc2-c2ccccc2F)CC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.56
NPC1 O15118 1/20 0.53
KMT2A Q03164 5/20 0.52
MEN1 O00255 4/20 0.52
MAPT P10636 1/20 0.52
DRD2 P14416 1/20 0.51
DRD4 P21917 1/20 0.51
DRD3 P35462 1/20 0.51
ATM Q13315 1/20 0.48
L3MBTL1 Q9Y468 3/20 0.46
KDM4E B2RXH2 3/20 0.45
LMNA P02545 3/20 0.44
MAPK1 P28482 1/20 0.44
POLB P06746 2/20 0.43
SSTR5 P35346 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2905339 0.93 ALDH1A1 (0.53) ALDH1A1NPC1KMT2AMEN1MAPT
SCHEMBL2908465 0.91 ALDH1A1 (0.53) ALDH1A1NPC1KMT2AMEN1MAPT
SCHEMBL2906130 0.86 CYP2A13 (0.53) ALDH1A1NPC1KMT2AMEN1MAPT
SCHEMBL2909895 0.84 DRD2 (0.56) ALDH1A1NPC1KMT2AMEN1MAPT
SCHEMBL2908931 0.80 ALDH1A1 (0.49) ALDH1A1NPC1KMT2AMEN1DRD2
SCHEMBL2902533 0.80 KMT2A (0.52) ALDH1A1KMT2AMEN1MAPTATM
SCHEMBL18965049 0.78 ALDH1A1 (0.52) ALDH1A1NPC1KMT2AMEN1MAPT
SCHEMBL2905010 0.76 KDM4E (0.48) ALDH1A1NPC1KMT2AMEN1MAPT
SCHEMBL2905435 0.76 KDM4E (0.53) ALDH1A1NPC1KMT2AMEN1MAPT
SCHEMBL2904861 0.74 POLB (0.55) ALDH1A1KMT2AMEN1DRD4L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A ALDH1A1 1336/4885NPC1 1748/4885KMT2A 2510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.